Background: Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a well-established predictor of response to the DNA-alkylating agent temozolomide in patients with glioblastoma.
Materials and methods: Pyrosequencing analysis was used to determine the MGMT promoter methylation status in 61 meningiomas, to clarify whether it might have a predictive role.
Results: Only two tumors (3%) had a mean methylation frequency higher than the cut-off value of 10% for the four CpG sites examined.
Conclusion: The methylation of the MGMT promoter is uncommon, or occurs at a low frequency in meningiomas. There is no convincing rationale to test such tumors for their MGMT methylation status in a clinical setting.
Keywords: MGMT promoter; Meningioma; methylation; predictive value; pyrosequencing.
Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.